Background: The aim of the current study was to estimate two protocols for HER2-negative locally recurrent or metastatic breast cancer patients, bevacizumab combined with paclitaxel versus bevacizumab combined with capecitabine, from the economic view. Methods: The process of HER2-negative locally recurrent or metastatic breast cancer treated with bevacizumab combined with paclitaxel or bevaciz­umab combined with capecitabine made up the decision model in our analysis. The primary objective was to show the incremental cost-effectiveness ratio (ICER). The critical parameters and the robustness of the model on the results of the analysis were assessed by univariate sensitivity analysis and probabilistic sensitivity analysis. Results: In the analysis, quality-adjusted life year (QALY) increased by 0.4 with bevacizumab plus paclitaxel compared with bevacizumab plus capecitabine, and incremental cost of USD 4,340.46. Therefore, the ICER was USD 27,252.875. The ICER exceeded the commonly accepted willingness to pay on the recommendation of the World Health Organization, which is defined as 3 times of the gross domestic product per capita of China in the model (USD 25,840.88 per QALY). On univariate analysis, it is found that the most significant affecting factor is the cost of progression-free survival state in the bevacizumab plus paclitaxel group. Besides, bevacizumab plus paclitaxel had a 47.8% probability of being cost-effective versus bevacizu­mab plus capecitabine according to probabilistic sensitivity analysis. Conclusions: Based on the results of the analysis, bevacizumab plus paclitaxel is unlikely to be a cost-effective option for patients with HER2-negative locally recurrent or metastatic breast cancer compared with bevacizumab plus capecitabine.

1.
Forouzanfar
MH
,
Foreman
KJ
,
Delossantos
AM
,
Lozano
R
,
Lopez
AD
,
Murray
CJ
, et al.
.
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
.
Lancet
.
2011
Oct
;
378
(
9801
):
1461
84
.
[PubMed]
0140-6736
2.
Fan
L
,
Strasser-Weippl
K
,
Li
JJ
,
St Louis
J
,
Finkelstein
DM
,
Yu
KD
, et al.
.
Breast cancer in China
.
Lancet Oncol
.
2014
Jun
;
15
(
7
):
e279
89
.
[PubMed]
1470-2045
3.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
.
Lancet
.
2005
May
;
365
(
9472
):
1687
717
.
[PubMed]
0140-6736
4.
Kennecke
H
,
Yerushalmi
R
,
Woods
R
,
Cheang
MC
,
Voduc
D
,
Speers
CH
, et al.
.
Metastatic behavior of breast cancer subtypes
.
J Clin Oncol
.
2010
Jul
;
28
(
20
):
3271
7
.
[PubMed]
0732-183X
5.
Cardoso
F
,
Fallowfield
L
,
Costa
A
,
Castiglione
M
,
Senkus
E
;
ESMO Guidelines Working Group
.
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2011
Sep
;
22
Suppl 6
:
vi25
30
.
[PubMed]
0923-7534
6.
Cardoso
F
,
Costa
A
,
Norton
L
,
Cameron
D
,
Cufer
T
,
Fallowfield
L
, et al.
1st International consensus guidelines for advanced breast cancer (ABC 1). breast.
2012
Jun;21(3):242-52.
7.
Oshaughnessy
JA
,
Blum
J
,
Moiseyenko
V
,
Jones
SE
,
Miles
D
,
Bell
D
, et al.
.
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
.
Ann Oncol
.
2001
Sep
;
12
(
9
):
1247
54
.
[PubMed]
0923-7534
8.
Smorenburg
CH
,
de Groot
SM
,
van Leeuwen-Stok
AE
,
Hamaker
ME
,
Wymenga
AN
,
de Graaf
H
, et al.
.
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
.
Ann Oncol
.
2014
Mar
;
25
(
3
):
599
605
.
[PubMed]
0923-7534
9.
Zielinski
C
,
Láng
I
,
Inbar
M
,
Kahán
Z
,
Greil
R
,
Beslija
S
, et al.;
TURANDOT investigators
.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
.
Lancet Oncol
.
2016
Sep
;
17
(
9
):
1230
9
.
[PubMed]
1470-2045
10.
Lang
I
,
Brodowicz
T
,
Ryvo
L
,
Kahan
Z
,
Greil
R
,
Beslija
S
, et al.;
Central European Cooperative Oncology Group
.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
.
Lancet Oncol
.
2013
Feb
;
14
(
2
):
125
33
.
[PubMed]
1470-2045
11.
Purmonen
T
,
Martikainen
JA
,
Soini
EJ
,
Kataja
V
,
Vuorinen
RL
,
Kellokumpu-Lehtinen
PL
.
Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
.
Clin Ther
.
2008
Feb
;
30
(
2
):
382
92
.
[PubMed]
0149-2918
12.
Petrou
PK
,
Talias
MA
.
Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus
.
Expert Rev Pharmacoecon Outcomes Res
.
2014
Feb
;
14
(
1
):
131
8
.
[PubMed]
1473-7167
13.
Peasgood
T
,
Ward
SE
,
Brazier
J
.
Health-state utility values in breast cancer
.
Expert Rev Pharmacoecon Outcomes Res
.
2010
Oct
;
10
(
5
):
553
66
.
[PubMed]
1473-7167
14.
Murray
CJ
,
Evans
DB
,
Acharya
A
,
Baltussen
RM
.
Development of WHO guidelines on generalized cost-effectiveness analysis
.
Health Econ
.
2000
Apr
;
9
(
3
):
235
51
.
[PubMed]
1057-9230
15.
Eichler
HG
,
Kong
SX
,
Gerth
WC
,
Mavros
P
,
Jönsson
B
.
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge
.
Value Health
.
2004
Sep-Oct
;
7
(
5
):
518
28
.
[PubMed]
1098-3015
16.
Elbasha
EH
,
Messonnier
ML
.
Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale
.
Health Econ
.
2004
Jan
;
13
(
1
):
21
35
.
[PubMed]
1057-9230
17.
Briggs
AH
,
Weinstein
MC
,
Fenwick
EA
,
Karnon
J
,
Sculpher
MJ
,
Paltiel
AD
;
ISPOR-SMDM Modeling Good Research Practices Task Force
.
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6
.
Med Decis Making
.
2012
Sep-Oct
;
32
(
5
):
722
32
.
[PubMed]
0272-989X
18.
Price
MJ
,
Briggs
AH
.
Development of an economic model to assess the cost effectiveness of asthma management strategies
.
Pharmacoeconomics
.
2002
;
20
(
3
):
183
94
.
[PubMed]
1170-7690
19.
Montero
AJ
,
Avancha
K
,
Glück
S
,
Lopes
G
.
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
.
Breast Cancer Res Treat
.
2012
Apr
;
132
(
2
):
747
51
.
[PubMed]
0167-6806
20.
Kourlaba
G
,
Rapti
V
,
Alexopoulos
A
,
Relakis
J
,
Koumakis
G
,
Chatzikou
M
, et al.
.
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: an economic evaluation study
.
BMC Health Serv Res
.
2015
Aug
;
15
(
1
):
307
.
[PubMed]
1472-6963
You do not currently have access to this content.